Clinical Trials Logo
  1. Home
  2. Microscopic Colitis
  3. NCT02303132

Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis

Microscopic Colitis Clinical Trial

Official title:
Ex Vivo Experiments to Evaluate the Role of Medication on the Colon Permeability in Microscopic Colitis

Clinical Trial Summary

Medication use, especially NSAIDs and PPIs, prior to diagnosis is considered a risk factor for MC development. However, the exact pathophysiological mechanism is unclear. It is hypothesized that NSAIDs, PPIs, and SSRIs may have an effect on the colon permeability, due to an idiosyncratic reaction which results in a local immune response. MC patients are considered to be susceptible hosts, prone to react on administration of abovementioned drugs. In order to test this hypothesis and to generate new insights in the pathophysiology of MC, we want to perform an Ussing chamber experiment using fresh colon tissue samples. The primary objective is to assess ex vivo the effect of NSAIDs and PPIs on epithelial permeability of colon biopsy specimens of MC and non-MC patients, using the Ussing chamber system

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02303132
Study type Interventional
Source Maastricht University Medical Center
Contact
Status Completed
Phase N/A
Start date November 2015
Completion date July 2016
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05998174 - Faecal Microbiota Transplantation for Microscopic Colitis Early Phase 1
Recruiting NCT05058131 - Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre N/A
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT06031064 - External Validation of a Microscopic Colitis Clinical Scoring System in Patients With Chronic Watery Diarrhoea
Recruiting NCT04043897 - Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis Phase 2
Recruiting NCT06172647 - Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer
Recruiting NCT03477032 - FMT in Inflammatory Bowel Disease
Completed NCT03275467 - Faecal Microbiota Transplantation in Patients With Microscopic Colitis N/A
Completed NCT01928667 - Case-Control Study to Identify Risk Factors for Microscopic Colitis N/A
Completed NCT00180050 - Budesonide Treatment for Lymphocytic Colitis Phase 3
Not yet recruiting NCT05915104 - Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Phase 2
Completed NCT00952952 - Trial of Mesalamine for the Treatment of Active Microscopic Colitis Phase 2/Phase 3